Showing 5061-5070 of 20470 results for "".
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://reachmd.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Advances in Nanomedicine: Overcoming Tumor Barriers for Enhanced Cancer Therapyhttps://reachmd.com/news/advances-in-nanomedicine-overcoming-tumor-barriers-for-enhanced-cancer-therapy/2485558/Advanced, stage-gated engineering reframes nanoparticle design as a sequential solution to systemic, stromal and cellular delivery barriers—improving tumor delivery while limiting off-target toxicity.
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://reachmd.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://reachmd.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- Reforming Prior Authorization in Medicare Advantage: AMA's Advocacy in Focushttps://reachmd.com/news/reforming-prior-authorization-in-medicare-advantage-amas-advocacy-in-focus/2485518/The American Medical Association (AMA) supports the Improving Seniors’ Timely Access to Ca
- The Critical Role of Cardiology Follow-Up in Perioperative Carehttps://reachmd.com/news/the-critical-role-of-cardiology-follow-up-in-perioperative-care/2485524/A large multicenter cohort study found a notable incidence of postoperative myocardial injury and linked rout
- AI-Supported Mammography Screening: A Leap Forward in Oncologyhttps://reachmd.com/news/ai-supported-mammography-screening-a-leap-forward-in-oncology/2485529/The MASAI randomized screening trial observed a descriptively lower proportion of interval breast cancers with unfavorable cha
- Key Highlights from Maui Derm Hawaii 2026: Emerging Dermatological Therapeutics and Future Directionshttps://reachmd.com/news/key-highlights-from-maui-derm-hawaii-2026-emerging-dermatological-therapeutics-and-future-directions/2485532/At Maui Derm Hawaii 2026, late-phase data highlighted topical JAK inhibitors (ruxolitinib) a
- Navigating the Transition: Pediatric to Adult Hospital Care for Complex Conditionshttps://reachmd.com/news/navigating-the-transition-pediatric-to-adult-hospital-care-for-complex-conditions/2485534/Young adults with childhood-onset complex chronic conditions (4Cs) experience substantially worse inpatient outcomes than their peers, with longer hospital stays and higher readmission rates following admission to adult hospitals. In
- Rezpegaldesleukin Demonstrates Broad Phase 2b Efficacy in Atopic Dermatitis and Asthmahttps://reachmd.com/news/rezpegaldesleukin-demonstrates-broad-phase-2b-efficacy-in-atopic-dermatitis-and-asthma/2485541/Rezpegaldesleukin significantly improved disease severity, itch, and asthma-related symptoms in patients with moderate-to-severe atopic dermatitis, according to “Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in a Phase 2b Trial,” a poster by